- 1 Title: COVID-19 vaccine effectiveness during a prison outbreak when the Omicron was the
- 2 dominant circulating variant— Zambia, December 2021
- 3
- 4 **Authors**: John Simwanza^{1,2}; Jonas Z. Hines³; Danny Sinyange^{1,2}; Nyambe Sinyange⁴;
- 5 Chilufya Mulenga^{1,4}; Sarah Hanyinza⁴; Patrick Sakubita⁴, Nelia Langa⁴; Haggai Nowa⁵;
- 6 Priscilla Gardner⁶; Ngonda Saasa⁷; Gabriel Chipeta⁶; James Simpungwe³; Warren
- 7 Malambo³; Busiku Hamainza²; Nathan Kapata⁴; Muzala Kapina⁴; Kunda Musonda⁴;
- 8 Mazyanga Liwewe⁴; Consity Mwale⁶; Sombo Fwoloshi⁹; Lloyd B. Mulenga⁹; Simon Agolory³;
- 9 Victor Mukonka⁴; Roma Chilengi^{4,10};
- 10

11 Affiliations:

- ¹Zambia Field Epidemiology Training Programme, Lusaka, Zambia
- 13 ²National Malaria Elimination Centre, Lusaka, Zambia
- ¹⁴ ³Centers for Disease Control and Prevention, Lusaka, Zambia
- ⁴Zambia National Public Health Institute, Lusaka, Zambia
- ⁵Zambia Prison Services, Lusaka, Zambia
- ⁶Lusaka District Health Office, Lusaka, Zambia
- ¹⁸ ⁷University of Zambia Veterinary Medicine Laboratory School, Lusaka, Zambia
- ¹⁹ ⁸Lusaka Province Health Office, Lusaka, Zambia
- ⁹Ministry of Health, Lusaka, Zambia
- ¹⁰Republic of Zambia State House, Lusaka, Zambia
- 22
- 23 Keywords: COVID-19 vaccines, vaccine efficacy; SARS-CoV-2 variants, prisons, prisoners,
- 24 Zambia, Africa

26 Abstract: During a COVID-19 outbreak in a prison in Zambia from 14th to 19th December

- 27 2021, a case control study was done to measure vaccine effectiveness (VE) against
- infection and symptomatic infection, when the Omicron variant was the dominant circulating
- variant. Among 382 participants, 74.1% were fully vaccinated and the median time since full
- 30 vaccination was 54 days. There were no hospitalizations or deaths. COVID-19 VE against
- any SARS-CoV-2 infection was 64.8% and VE against symptomatic SARS-CoV-2 infection
- 32 was 72.9%. COVID-19 vaccination helped protect incarcerated persons against SARS-CoV-
- 33 2 infection during an outbreak while Omicron was the dominant variant in Zambia.
- 34

35

36

38 Introduction

39	COVID-19 continues to ravage the globe as new SARS-CoV-2 variants emerge and cause
40	new waves of infections. The highly transmissible Omicron variant emerged in late 2021,
41	rapidly spreading to many countries and leading to record-breaking case counts globally. In
42	early December 2021, Zambia recorded a rapid rise in confirmed COVID-19 cases,
43	coinciding with confirmation of the Omicron variant in the country. Zambia recorded a daily
44	average of 1,422 confirmed COVID-19 cases in December 2021, compared to an average
45	15 cases daily the previous month, in November 2021. From December 4^{th} to 24^{th} , 2021, all
46	sequenced specimens in Zambia were of the Omicron variant (1).
47	Congregate living settings, including prisons, are at high risk for COVID-19 outbreaks (2).
48	Congested living conditions make physical distancing and avoidance of crowds challenging
49	in many prison settings. Although difficult to enforce, use of face masks in high SARS-CoV-2
50	transmission risk settings can limit the rapid spread of infection (3).
51	On December 14 th , 2021, after not recording any COVID-19 cases for months, a local prison
52	in Lusaka noted an increase in the number of residents with respiratory symptoms, 19 of
53	whom tested positive for COVID-19 with rapid diagnostic tests (RDTs). The prison notified
54	the Lusaka District Health Office on the same day and an outbreak investigation was
55	initiated. Mitigation measures were reinforced, including mask distribution and mandatory
56	masking, cohorting persons testing positive and provision of hand hygiene stations
57	throughout the prison. Of 767 persons incarcerated at the facility during the outbreak, 241
58	(31.4%) tested positive for COVID-19 from December 14 th to 19 th , 2021.
59	COVID-19 vaccines have shown remarkable effectiveness, particularly for reducing COVID-
60	19 severity (4). COVID-19 vaccine effectiveness (VE) against the Omicron variant is lower
61	than against other variants (5,6), although data from the African continent are limited (7–9).
62	Correctional services in Zambia achieved high COVID-19 vaccine coverage among
63	incarcerated persons prior to the Omicron variant wave through onsite vaccination clinics

64	and enhanced COVID-19 screening and testing with encouragement of vaccination for those
65	testing negative. Of the incarcerated persons at this local prison, 619 (80.7%) were
66	vaccinated when the outbreak occurred (compared to 12.6% of the eligible general
67	population in Zambian at the time). We measured VE among incarcerated persons during
68	this outbreak in Zambia.
69	

70 Methods

71 A case-control study of SARS-CoV-2 infection and symptomatic infection by vaccination

status was conducted among persons incarcerated at the prison facility during the outbreak

from 15th to 20th December 2021. The facility is in Lusaka, the national capital of Zambia,

and houses men aged ≥13 years awaiting court cases or transfer to other prisons after

sentencing. The prison has five cells built to house 92 persons, although at the outbreak

onset 767 persons were incarcerated (i.e., > 800% beyond capacity).

77 During the outbreak, all incarcerated persons were tested for COVID-19 using Panbio

78 COVID-19 Ag rapid test (Abbott Rapid Diagnostics Jena GmbH, Germany) from December

⁷⁹ 14th to 19th, 2021. Cases and controls were incarcerated persons testing COVID-19 positive

and negative, respectively. Participants were recruited into the study between December

20th to 24th, 2021 by reviewing the outbreak line list maintained by the prison health team

and district health office, attempting to frequency match controls by cases' cell assignment.

Verbal consent was obtained from the participants and for minors aged 13–17 years.

84 Consent was obtained from the prison warden as per Zambia Correctional Services policy.

85 This study was approved by the ERES Ethics review board and National Health Research

86 Authority. The activity was reviewed by US Centers for Disease Control and Prevention and

87 was conducted consistent with applicable Federal law and CDC policy.

A standardized questionnaire that included information on demographics and medical
 history, including COVID-19 vaccination and test results was administered by trained

interviewers. Self-reported COVID-19 test results were confirmed with the line list where the
 RDT results were recorded. Vaccination status was cross-referenced with the national
 registry.

Full vaccination was defined as having received the 1st dose of a one-dose vaccine or 2nd 93 94 dose of a two-dose vaccine ≥14 days before COVID-19 testing. Partial vaccination was defined as having received the 1st dose of a two-dose vaccine ≥14 days before COVID-19 95 testing but not the 2^{nd} dose yet or receiving the 2^{nd} dose ≤ 13 days before testing. Persons 96 97 who were partially vaccinated or indeterminate status (i.e., received their 1st dose of the One 98 dose vaccine 0-13 days before testing, or had an unknown type of COVID-19 vaccine) were 99 excluded from analyses. Multivariable logistic regression was used to calculate the odds of 100 SARS-CoV-2 infection and symptomatic infection, adjusting for age, number of 101 comorbidities, jail cell, and self-reported mask use. VE was calculated as 1 minus the 102 adjusted odds ratio times 100. To reduce the risk of misclassification bias related to false negative RDT test results, we conducted a sensitivity analysis excluding symptomatic 103 104 controls.

105

106 Results

107 In total, 385 (50.2%) of the 767 incarcerated persons present during the outbreak were 108 reached for interview and 382 (49.8%) consented to being enrolled in the study. All were 109 males, with a median age of 28 years (interguartile range [IQR]: 21-36 years) (Table 1). 110 Overall, 84 (22.0%) had at least one comorbidity, with HIV being most common (n = 40, 111 10.5%). Only 16 (4.1%) reported having had COVID-19 previously. 112 Overall, 294 (77.0%) participants received ≥1 COVID-19 vaccine dose; of these 283 (96.3%) 113 were fully vaccinated, 1 (0.3%) partially vaccinated and 10 (3.4%) indeterminate. Among 114 fully vaccinated participants, 253 (89.4%) received the one-dose Janssen vaccine and 30 115 (10.6%) received the two-dose AstraZeneca vaccines. None had received an additional

116 ('booster') vaccine dose. The median time since receipt of a full primary vaccine series was

117 54 days (IQR: 28-85 days).

There were 180 (47.1%) COVID-19 positive incarcerated persons (i.e., cases) and 202
(52.9%) COVID-19 negative persons (i.e., controls). Among positive cases, 117 (65.0%)
were in fully vaccinated persons (i.e., breakthrough infections). Of the 16 (4.1%) persons
reporting prior confirmed COVID-19, 5 (29.4%) were positive during the outbreak (i.e.,
reinfections).

123 Overall, 104 (27.2%) persons reported any COVID-19 symptoms, with a greater proportion

among cases (45.6% vs. 10.9%; p <0.01, chi-square test). The most common symptoms

among COVID-19 cases were cough (37.8%), rhinorrhoea (20.6%), headache (17.2%), and

myalgias (12.8%) (Table 1). Eighty-nine (49.4%) of the 180 participants with cases sought

127 medical care at the prison clinic, and none (0%) were admitted or died. Cases were more

128 likely to have sought health care. There were no differences among the cases and controls

in terms of age, number of comorbidities, prior Covid-19, or mask use.

130 Cases were less likely to be fully vaccinated than controls (66.9% versus 84.7%; p<0.01,

131 chi-square test) (Table 2). VE against SARS-CoV-2 infection was 64.8% (95% confidence

interval [CI]: 36.1-81.0%) and VE against symptomatic SARS-CoV2 infection was 72.9%

133 (95% CI: 42.0-87.5%). The median time to vaccination was less than two months and the VE

134 was higher for those vaccinated within the past 60 days compared to >60 days before

135 COVID-19 testing, although the confidence intervals overlapped (VE for SARS-CoV-2

136 infection: 74.6% [95% CI: 50.3-87.4%] vs. 54.2% [95% CI: 6.9-77.9%], respectively). VE of

137 Janssen vaccine against SARS-CoV-2 infection was 63.6% (95% CI: 33.6-80.5%) and

against symptomatic infection was 73.0% (95% CI: 41.6-87.7%). VE of AstraZeneca against

139 SARS-CoV-2 infection was 89.4% (95% CI: 59.5-97.8%) and against symptomatic infection

140 was 83.7% (95% CI: 60.8-93.6%). The sensitivity analysis excluding symptomatic controls

141 did not meaningfully change the VE estimates (VE against SARS-CoV-2 infection was

142 64.1% [95% CI: 35.8-80.2%] and VE against symptomatic SARS-CoV2 infection was 73.4%

143 [95% CI: 44.6-87.4%]). Forty persons (10.5%) in the analysis reported being HIV positive,

among who 83.3% of unvaccinated PLHIV tested SARS-CoV-2 positive compared to 50.0%

of fully vaccinated PLHIV (p = 0.20, chi-square test). Among PLHIV, VE against SARS-CoV-

- 146 2 infection was 82.2% (95% CI: -107-99.4%).
- 147

148 Discussion

149 During a prison COVID-19 outbreak in Zambia, COVID-19 vaccination protected against

150 SARS-CoV-2 infection and symptomatic illness while Omicron was the dominant strain in the

151 country (1). These findings provide important evidence that might help increase COVID-19

152 vaccination in Zambia, where many more Zambians need to be vaccinated to reach the

153 African Union targets adopted by the country (10).

154 The SARS-CoV-2 Omicron variant contains numerous mutations to the spike protein which 155 may lead to immune evasion. VE estimates reported here are lower compared to prior 156 strains (11,12), and the high proportion of breakthrough infections in this outbreak supports 157 in theory the possibility of immune evading capability of Omicron. In this study, VE was 158 higher for symptomatic illness than any infection; VE for severe illness could not be 159 accessed because no persons were hospitalized or died during this outbreak although other 160 studies have demonstrated durability against this important outcome (13). Similarly, VE of a 161 booster dose could not be assessed because Zambia did not begin offering a booster dose 162 until January 2022. The relatively short time since vaccination might explain the relatively 163 higher effectiveness findings against Omicron (6,14,15), although there was a suggestion of 164 waning immunity when comparing the VE point estimates of participants fully vaccinated 165 over two months before the outbreak with those vaccinated within the past two months. Our 166 findings are encouraging considering alarm raised early in the Omicron wave about the

167 vaccines widely available in Africa being ineffective against reducing SARS-CoV-2

transmission (16).

Notably, symptomology was mild among participants, which is consistent with reports from other countries that are experiencing Omicron surges (9,17). Animal evidence suggests this might be related to tropism of Omicron for upper respiratory epithelium relative to the lower respiratory tract (18). This finding might also reflect the relatively younger age of persons in this outbreak. The role of pre-existing immunity in Zambia from natural infection remains uncertain and serosurveys would be useful to understand to what proportion of people in Zambia have been infected with SARS-CoV-2.

176 This study had several limitations. All cases were confirmed with RDTs, which have lower

177 sensitivity than PCR tests (19). Additionally, beyond initial test results, serial testing was not

available meaning some controls might have been in their incubation period at the time of

testing and therefore misclassified. Omicron was not confirmed by genomic sequencing in

this outbreak, so the outbreak could have been from another strain; however, Omicron was

already dominant in Zambia before this outbreak occurred (20). Lastly, although few

182 participants reported a prior confirmed SARS-CoV-2 infection, the actual number might be

183 much higher considering only a small proportion of cases are confirmed in Zambia (21).

184 Rapid investigation of an outbreak in a closed setting demonstrated VE of COVID-19

vaccines against Omicron infection in Zambia. COVID-19 vaccination remains a critical tool

in decreasing SARS-CoV-2 transmission and severity especially when coupled with a

187 layered prevention including well-fitting facemask use, hand hygiene, limiting large

gatherings, and adequate ventilation and/or outdoor gatherings. Continuing to rapidly scale

189 COVID-19 vaccination to all eligible persons in Zambia can help prevent SARS-CoV-2

190 transmission and symptomatic COVID-19.

191

193

- 194 Attribution of Support. This work has been supported by the President's Emergency Plan for
- AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) and
- 196 the CDC Emergency Response to the COVID-19 pandemic.
- 197
- 198 Disclaimer. The findings and conclusions in this report are those of the author(s) and do not
- 199 necessarily represent the official position of the funding agencies. Use of trade names is for
- 200 identification only and does not imply endorsement by the funding agencies.

202 References

203	1.	GISAID - EpiCov [Internet]. [cited 2022 Feb 18]. Available from:
204		https://www.epicov.org/epi3/frontend#220b8c
205	2.	Hagan LM, McCormick DW, Lee C, Sleweon S, Nicolae L, Dixon T, et al. Outbreak of
206		SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a
207		Federal Prison — Texas, July–August 2021. MMWR Morb Mortal Wkly Rep. 2021
208		Sep;70(38):1349–54.
209	3.	Centers for Disease Control and Prevention (CDC). Science Brief: Community Use of
210		Masks to Control the Spread of SARS-CoV-2 [Internet]. December 6, 2021. [cited
211		2022 Mar 5]. Available from: https://www.cdc.gov/coronavirus/2019-
212		ncov/science/science-briefs/masking-science-sars-cov2.html
213	4.	Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
214		COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022
215		Jan;114:252–60.
216	5.	Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al.
217		Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of
218		concern. medRxiv [Internet]. 2021 Dec;2021.12.14.21267615. Available from:
219		https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1%0Ahttps://www.m
220		edrxiv.org/content/10.1101/2021.12.14.21267615v1.abstract
221	6.	Thompson MG, Natarajan K, Irving SA. Effectiveness of a Third Dose of mRNA
222		Vaccines Against COVID-19–Associated Emergency Department and Urgent Care
223		Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron
224		Variant Predominance — VISION Network, 10 States, August 2021–. Morb Mortal
225		Wkly Rep [Internet]. ePub: 21 J. Available from:
226		https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#sugg
227		estedcitation

- 228 7. Grey GE, Collie S, Garrett N, Goga A, Champion J, Zylstra M, et al. Vaccine
- 229 effectiveness against hospital admission in South African health care workers who
- received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave:
- 231 Preliminary Results of the Sisonke 2 Study. medRxiv [Internet]. Available from:
- 232 https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1
- 8. Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al.
- 234 Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa
- 235 (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation
- 236 study. Lancet (London, England). 2022 Mar;399(10330):1141–53.
- Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2
 Vaccine against Omicron Variant in South Africa. Vol. 386, The New England journal
 of medicine. 2022. p. 494–6.
- 240 10. World Health Organization (WHO). Leaders Make Urgent Call To Accelerate
- 241 Vaccination Globally And In Africa [Internet]. Geneva, Switzerland; Available from:
- 242 https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-
- 243 vaccination-globally-and-in-africa
- 11. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al.
- 245 Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson &
- 246 Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without
- 247 Immunocompromising Conditions United States, March–August 2021. MMWR
- 248 Morb Mortal Wkly Rep. 2021 Sep;70(38):1337–43.
- Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of
 Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022 Jan;
- 13. Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al.
- 252 Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive
- 253 Mechanical Ventilation and Death United States, March 2021-January 2022. MMWR

254 Morb Mortal Wkly Rep. 2022 Mar;71(12):459–65.

- Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19
 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022
 Apr;386(16):1532–46.
- 258 15. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning
- 259 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated
- 260 Emergency Department and Urgent Care Encounters and Hospitalizations Among
- 261 Adults During Periods of Delta and Omicron Variant Predominance VISION Network,
- 262 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022
- 263 Feb;71(7):255–63.
- 16. Nolen S. Most of the World's Vaccines Likely Won't Prevent Infection From Omicron.
- 265 The New York Times [Internet]. Available from:
- 266 https://www.nytimes.com/2021/12/19/health/omicron-vaccines-efficacy.html
- 267 17. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics
- 268 and Outcomes of Hospitalized Patients in South Africa During the COVID-19
- 269 Omicron Wave Compared With Previous Waves. JAMA. 2021 Dec;
- 270 18. Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, et al. SARS-CoV-2
- 271 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta
- 272 variants strains in a mouse model of severe COVID-19. bioRxiv. 2021
- 273 Dec;2021.12.26.474085.
- 19. Akingba OL, Sprong K, Marais G, Hardie DR. Field performance evaluation of the
- 275 PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant
- in the Eastern Cape, South Africa. J Clin Virol Plus [Internet]. 2021;1(1–2):100013.
- 277 Available from: https://doi.org/10.1016/j.jcvp.2021.100013
- 278 20. Mwenda-Chimfwembe M, Saasa N, Bridges D. Genomic epidemiology of novel

- 279 coronavirus Africa_Zambia-focused subsampling [Internet]. [cited 2022 Feb 16].
- 280 Available from: https://nextstrain.org/groups/SC2ZamPub/ncov/africa/zambia
- 281 21. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence
- of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster
- sample survey. Lancet Glob Heal. 2021;(21):1–9.
- 284

Table 1. Characteristics and outcomes of cases and controls during an COVID-19 outbreak

in a prison in Zambia, December 2021

Variable	Cases* (N=180)	Controls* (N=202)	p-value [†]
Age, median years (IQR)	27 (21-36)	28 (21-36)	0.58
Imprisonment duration, median days (IQR)	41 (13-96)	43 (17-120)	0.79
Education level, n (%) None Primary Secondary Tertiary	5 (2.8) 68 (37.8) 82 (45.6) 25 (13.9)	5 (2.5) 63 (31.2) 111 (55) 23 (11.4)	0.34
Nationality, n (%) Zambian Other	143 (79.4) 37 (20.6)	176 (87.1) 26 (12.9)	0.06
Any comorbidity, n (%) [‡]	38 (21.1)	46 (22.8)	0.79
Comorbidity type, n (%) HIV Hypertension Cardiac disease Diabetes Renal disease Pulmonary disease Tuberculosis Liver disease Other	$\begin{array}{c} 22\ (12.2)\\9\ (5.0)\\2\ (1.1)\\1\ (0.6)\\2\ (1.1)\\1\ (0.6)\\1\ (0.6)\\1\ (0.6)\\6\ (3.4)\end{array}$	$\begin{array}{c} 18 \ (8.9) \\ 5 \ (2.5) \\ 4 \ (2.0) \\ 5 \ (2.5) \\ 2 \ (1.0) \\ 1 \ (0.5) \\ 2 \ (1.0) \\ 1 \ (0.5) \\ 14 \ (7.1) \end{array}$	0.38 0.30 0.79 1.00 0.92 1.00 1.00 1.00 0.18
Prior COVID-19, n (%)	5 (2.8)	11 (5.4)	0.13
Mask use Always or most of the time Sometimes or rarely Don't use a mask	97 (53.9) 51 (28.3) 32 (17.8)	106 (52.5) 72 (35.6) 24 (11.9)	0.14
Timing of 1st Vaccine Dose, n (%) ≥14 days before testing 0-13 days before testing [¶] After testing Not vaccinated	118 (65.0) 4 (2.2) 0 (0.0) 58 (32.2)	168 (83.2) 4 (2.0) 0 (0.0) 30 (14.9)	<0.01
Vaccine type (n = 294), n (%) Janssen (J&J) AstraZeneca Not known	110 (90.2) 11 (9.0) 1 (0.8)	151 (87.8) 20 (11.6) 1 (0.6)	0.75
Vaccination status, n (%)** Fully Partially Indeterminate Unvaccinated	117 (65.0) 0 (0.0) 5 (2.8) 58 (32.2)	166 (82.2) 1 (0.5) 5 (2.5) 30 (14.9)	<0.01

Time since vaccination, median days (IQR)	56 (33-91)	53 (27-84)	0.02
Symptomatic, n (%)	82 (45.6)	22 (10.9)	<0.01
Symptoms, n (%) Cough	68 (37.8)	18 (8.9)	1.00
Rhinorrhea	37 (20.6)	6 (3.0)	0.21
Headache	31 (20.6)	6 (3.0)	0.51
Myalgia	23 (12.8)	2 (1.0)	0.12
Fever	18 (10.0)	3 (1.5)	0.57
Fatigue	10 (5.6)	1 (0.5)	0.52
Sore throat	9 (5.0)	6 (3.0)	1.00
Chills	6 (3.3)	2 (1.0)	1.00
Sinus congestion	3 (1.7)	1 (0.5)	NC
Loss of taste	2 (1.1)	0 (0.0)	NC
Loss of smell	2 (1.1)	0 (0.0)	NC
Others	5 (2.8)	2 (1.0)	NC
Sought health care, n (%)	89 (49.4)	17 (8.4)	<0.01
Admitted to hospital, n (%)	0 (0.0)	0 (0.0)	NC
Died, n (%)	0 (0.0)	0 (0.0)	NC

* Cases were participants with a positive SARS-CoV-2 rapid diagnostic test (RDT) results and controls were participants with a negative RDT result

[†] Student's t-test for continuous variables and chi-square test or Fischer exact test (where any cell size <10) for categorical variables

[‡] Comorbidities included: hypertension, cardiac disease, obesity, pulmonary disease, kidney disease, liver disease, diabetes, cancer, HIV, and tuberculosis (current or past)

[¶] Participants classified as indeterminate because immune status at time of testing was unknown

** Partial vaccination was defined has having received the 1st dose of a two-dose vaccine \geq 14 days before COVID-19 testing but not the second dose or the 2nd dose \leq 13 days before testing. Full vaccination was defined having received the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine \geq 14 days before COVID-19 testing. Persons who were vaccinated with their 1st dose 0-13 days before testing were considered to have indeterminate vaccination status and excluded from analyses. IQR: interguartile range; NC: not calculated

Table 2. COVID-19 vaccine effectiveness against Omicron variant - Zambia, December 2021 290

Vaccination status	Fully vaccinated, n (%)		Vaccine effectiveness, % (95% CI)*	
Vaccination status	Cases	Controls	SARS-CoV-2 infection	Symptomatic infection
Vaccine brand [†] Any vaccine (n = 371) Janssen (n = 341) AstraZeneca (n = 118)	117 (66.9) 106 (64.6) 11 (15.9)	166 (84.7) 147 (83.1) 19 (38.8)	64.8 (36.1-81.0) 63.6 (33.6-80.5) 89.4 (59.5-97.8)	72.9 (42.0-87.5) 73.0 (41.6-87.7) 85.1 (19.5-98.0)
Vaccination timing [†] ≤60 days (n = 249) >60 days (n = 210)	59 (50.4) 58 (50.0)	102 (77.3) 64 (68.1)	74.6 (50.3-87.4) 54.2 (6.9-77.9)	83.7 (60.8-93.6) 53.2 (-16.6-81.6)

* Adjusted for age, number of comorbidities, jail cell, and mask use [†] Analysis presented for fully vaccinated persons only. One person was partially vaccinated and 10 were indeterminate vaccination status (i.e., vaccinated with their 1st dose 0-13 days before COVID-19 testing) CI: confidence interval